Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (Becton, Dickinson and Company) will hold a virtual investor day on November 12, 2021, starting at 8 a.m. The event, lasting approximately four hours, will feature presentations from CEO Tom Polen and the executive leadership team, followed by Q&A sessions. A replay and additional materials will be available on BD's investor page after the event. BD is a global leader in medical technology, committed to enhancing healthcare through innovative solutions. For more information, visit bd.com.
BD (Becton, Dickinson and Company) has announced the shipment of its first over-the-counter (OTC) COVID-19 rapid antigen test, utilizing smartphone computer vision technology for result interpretation. Available for $39.99 with promotional pricing at $26.50 on Amazon, the BD Veritor™ test offers digital results in 15 minutes, simplifying at-home testing. It features automated reporting to health agencies and is suitable for individuals aged 14 and older. Authorized under Emergency Use Authorization, the test addresses common at-home testing challenges, including result interpretation and reporting.
BD (Becton, Dickinson and Company) announced the appointment of Dr. Carrie L. Byington to its board of directors, increasing the board to 13 members. Byington is the executive vice president and head of University of California Health, leading a $20 billion academic health system. Her experience includes significant roles at Texas A&M University and the University of Utah. The company views her appointment as timely, aligning with its BD 2025 strategy aimed at innovating in connected care and improving chronic disease outcomes.
On October 18, 2021, BD (Becton, Dickinson and Company) announced its new ESG strategy, Together We Advance, aimed at enhancing its commitment to health, community, and environmental stewardship. This strategy focuses on four pillars: Company Health, Planet Health, Community Health, and Human Health. BD set ambitious 2030 goals, including a 46% reduction in Scope 1 and 2 greenhouse gas emissions and carbon neutrality in direct operations by 2040. The strategy emphasizes climate change, responsible supply chains, and transparency, while aligning with the UN Sustainable Development Goals.
BD (Becton, Dickinson and Company) announced enhanced manufacturing capacity for injection devices to support U.S. vaccination efforts. Completed with the Department of Health and Human Services (HHS), the new lines bolster domestic supply amid ongoing COVID-19 challenges. This follows a $42 million investment from HHS in a previous capital project aimed at expanding BD's operations in Nebraska, underscoring a commitment to both current and future pandemic needs. BD has supplied hundreds of millions of devices, ensuring continuity in healthcare delivery as the flu season approaches.
BD (Becton, Dickinson and Company) has received 510(k) clearance from the FDA for the Rotarex™ Atherectomy System, expanding its indications to include treatment in peripheral arteries with stents, stent grafts, and bypasses. This device can now assist in the treatment of in-stent restenosis, a complication often arising in patients with peripheral arterial disease (PAD). With over a decade of clinical use, the Rotarex™ System is recognized for its efficacy in effectively managing arterial lesions and improving patient outcomes.
BD (Becton, Dickinson and Company) will report its fiscal 2021 fourth quarter and full year financial results on Nov. 4, 2021. A press release will be issued at approximately 6 a.m. ET, followed by a conference call and webcast at 8 a.m. ET to discuss the results and company strategy. Investors can access the webcast on BD's investor relations website. BD is a leading global medical technology company committed to improving healthcare through innovative technologies.
BD (Becton, Dickinson and Company) has joined the Race to Zero and the Business Ambition for 1.5°C, pledging to achieve net-zero emissions by 2050. This initiative aims to combat climate change, with commitments to reduce Scope 1 and 2 GHG emissions by 46% by 2030 and to be carbon neutral by 2040. The announcement will be celebrated on September 25, 2021, at the Global Citizen LIVE.
BD (Becton, Dickinson and Company) has been selected by Washington state to provide its BD Veritor™ Plus rapid antigen test for COVID-19 in K-12 schools. This easy-to-use test delivers results in just 15 minutes and will be available at no cost through a partnership with the Washington Department of Health. Schools can opt for a full-service testing program managed by Premier Medical Group, which will oversee testing protocols and result reporting. This service aims to keep schools open and safe while containing COVID-19 spread. The BD Veritor™ Plus system is authorized for emergency use, pending FDA clearance.
Vicarious Surgical and D8 Holdings Corp. have secured an additional
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
